Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
Overview
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations is a phase 1/2 interventional study registered as NCT07640295 by Jacobio Pharmaceuticals Co., Ltd., with 80 participants planned, started 2026-07-16 and due to reach its primary completion in 2029-12-31. Interventions recorded: JAB-23E73 tablet，nab-paclitaxel，gemcitabine.
Similar pages
not linked directly; found by shared links- TrialJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialA Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialJAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.